Status:
COMPLETED
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
Lead Sponsor:
Tanabe Pharma Corporation
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.
Detailed Description
This is a randomized, 3-arm, parallel group, double blind study to evaluate the efficacy and safety of TA-7284 in Japanese patients with Type 2 diabetes mellitus, who are not optimally controlled on d...
Eligibility Criteria
Inclusion
- Men or women age ≥20 years old
- Diagnosed with Type 2 diabetes mellitus at least 3 months before run-in period
- HbA1c of ≥7.0% and ≤10.0%
Exclusion
- Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus
- Past or current history of severe diabetic complications
- Fasting plasma glucose \> 270 mg/dL before treatment start
- History of hereditary glucose-galactose malabsorption or primary renal glucosuria
- Patients requiring insulin therapy
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
272 Patients enrolled
Trial Details
Trial ID
NCT01413204
Start Date
July 1 2011
End Date
August 1 2012
Last Update
January 8 2026
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Reserch site
Chūbu, Japan
2
Reserch site
Kanto, Japan
3
Reserch site
Kinki, Japan
4
Reserch site
Shikoku, Japan